News

Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference

ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and…

2 years ago

Poko Innovations Qualify As Finalists Across Multiple Award Categories At World CBD Awards

Cannmed announced as a finalist at the World CBD Awards for Best CBD White Label BrandCanndid announced as a finalist…

2 years ago

Empower Clinics Revenues Increase Substantially

3,000 Tests and appointments completed since June 1st add to increased revenue across divisionsVANCOUVER, BC / ACCESSWIRE / June 13,…

2 years ago

cbdMD, Inc. CEO Steps Down

Martin Sumichrast resigns as CEO, Board MemberCharlotte, North Carolina--(Newsfile Corp. - June 13, 2022) - cbdMD, Inc. (NYSE American: YCBD)…

2 years ago

CENTR Brands Corp Announces Arjan Chima as New Chief Executive Officer

Founder and current CEO Joseph E. Meehan will assume new role as CENTR's Founder and Board Chairman. Founder and current…

2 years ago

Innovaccer Named to AVIA Connect’s Top 50 Companies in Remote Patient Monitoring Report

Innovaccer’s remote patient monitoring has been recognized by AVIA Connect for its role in advancing virtual acute care solutions to…

2 years ago

LENSAR® Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment System

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser…

2 years ago

Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil

GENEVA, SWITZERLAND / ACCESSWIRE / June 13, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to…

2 years ago

Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL

In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated…

2 years ago

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell…

2 years ago